BiotechTV

•

Canal • 5 programas

Ciencias de la vida

Ciencias de la vida

2 feb
Ciencias de la vida

Ciencias de la vida

31 may
Ciencias de la vida

Ciencias de la vida

5 mar
Ciencias de la vida

Ciencias de la vida

Cada dos semanas
Ciencias de la vida

Ciencias de la vida

23 abr

02/06/2025

ASCO 2025: Protagonist Therapeutics' CEO Dinesh Patel discusses the results of the phase 3 study of Rusfertide for polycythemia vera, plus a recap of recent ulcerative colitis data for its IL-23R

He describes the Rusfertide result, which is partnered with Takeda and was presented in a plenary session at ASCO. Plus, he covers a UC announcement that JNJ made in March, and guides for when Protagonist will announce an obesity program.

02/06/2025

•

15 min
5 may

London based Cytospire Therapeutics has announced an $83M series A financing to develop first-in-class pan-gamma delta T-cell engagers - the lead program is an EGFR targeting solid tumors

Co-Founder & CEO Natalie Mount discusses the raise, and explains why she believes gamma delta T-cell engagers have advantages over CD3s. After presenting preclinical data at the recent AACR annual meeting, the lead EGFR program is preparing to go into the clinic.

5 may

•

17 min
17/10/2024

Gene therapy experts TJ Cradick and Andrew Kernytsky discuss the issues surrounding unintended off-target editing of genetic tools like CRISPR

For this high-tech emerging field within biotech, it is important to get safety right. They discuss the keys to understanding the possible range of edits, choosing the right assay, assessing and reporting the possible outcomes, and more.

17/10/2024

•

27 min
14/06/2025

EHA 2025: MaaT Pharma presented an update for its microbiome based treatment for GVHD, Xervyteg, which it has now filed for approval with the EMA

CMO Gianfranco Pittari walks us through data from the pivotal ARES study that MaaT announced in January and filed with the EMA. Plus, an EHA presentation from an early access program that is a follow-up from data we saw in ASH in December.

14/06/2025

•

13 min
25/04/2025

Talking chromatin regulation at Foghorn Therapeutics - whose partner Lilly will have preclinical data at AACR highlighting how the lead SMARCA2 program could do in combinations with other therapies

CEO Adrian Gottschalk describes chromatin regulation at a high level, and walks us through the Lilly partnership targeting SMARCA2, and Foghorn's independent programs targeting CBP, EP300, and ARID1B.

25/04/2025

•

19 min
25/03/2025

At an R&D event hosted by the company in Kendall Square today, Alloy Therapeutics' CEO Errik Anderson talked the latest in science regarding bispecifics, TCR mimics, genetic medicines, and more

He described the discovery work that Alloy does with its client partners, and highlighted emerging areas of science. Plus, the importance of good murine models, and his take on Chinese competition.

25/03/2025

•

22 min
05/08/2025

From Indianapolis: Adipo Therapeutics is approaching the obesity space by trying to turn energy storing 'white' fat into energy burning 'brown' fat

CEO Karen Wurster describes the science behind the company, which recently presented proof-of-concept data from human cells at the ADA meeting. Plus, what it is like working from the IBRI in Indianapolis and being an Indiana biotech company.

05/08/2025

•

6 min
17/06/2025

BIO International 2025: eGenesis CEO Mike Curtis discusses the case of the second patient who has received a transplant using the company's genetically engineered porcine kidney, and what is next

He describes the successful transplant of Tim Andrews, who threw out the first pitch at a Red Socks game last week, and discusses what is next for this program. Plus, the status of liver and heart programs.

17/06/2025

•

7 min
18/09/2025

Sweden's Annoca announced a $46M raise last month to help move its first TCR-T program into the clinic for KRAS-driven pancreatic cancer. CEO Reagan Jarvis tells us about that work and more.

He describes the raise and the trial, which is an umbrella study that will test products against three different mutations. Plus, work on vaccines and a non-oncology cell therapy program, and partnership opportunities.

18/09/2025

•

13 min
19/11/2024

A patient advocacy group founded by two parents has partnered with a biotech company on a gene therapy for limb-girdle muscular dystrophy Type 2C/R5 - it was just cleared to start a clinical trial

Dion Foundation Co-Founder and President Courtney Dion discusses with Atamyo Therapeutics CEO Stéphane Degove the many ways that patient advocate groups can support the work that biotech companies do.

19/11/2024

•

20 min

BiotechTV covers the biotechnology sector through news, stories, podcasts, and educational videos.

Sitio web

BiotechTV

Top programas

ASCO 2025: Protagonist Therapeutics' CEO Dinesh Patel discusses the results of the phase 3 study of Rusfertide for polycythemia vera, plus a recap of recent ulcerative colitis data for its IL-23R

London based Cytospire Therapeutics has announced an $83M series A financing to develop first-in-class pan-gamma delta T-cell engagers - the lead program is an EGFR targeting solid tumors

Gene therapy experts TJ Cradick and Andrew Kernytsky discuss the issues surrounding unintended off-target editing of genetic tools like CRISPR

EHA 2025: MaaT Pharma presented an update for its microbiome based treatment for GVHD, Xervyteg, which it has now filed for approval with the EMA

Talking chromatin regulation at Foghorn Therapeutics - whose partner Lilly will have preclinical data at AACR highlighting how the lead SMARCA2 program could do in combinations with other therapies

At an R&D event hosted by the company in Kendall Square today, Alloy Therapeutics' CEO Errik Anderson talked the latest in science regarding bispecifics, TCR mimics, genetic medicines, and more

From Indianapolis: Adipo Therapeutics is approaching the obesity space by trying to turn energy storing 'white' fat into energy burning 'brown' fat

BIO International 2025: eGenesis CEO Mike Curtis discusses the case of the second patient who has received a transplant using the company's genetically engineered porcine kidney, and what is next

Sweden's Annoca announced a $46M raise last month to help move its first TCR-T program into the clinic for KRAS-driven pancreatic cancer. CEO Reagan Jarvis tells us about that work and more.

A patient advocacy group founded by two parents has partnered with a biotech company on a gene therapy for limb-girdle muscular dystrophy Type 2C/R5 - it was just cleared to start a clinical trial

Acerca de

BiotechTV

Top programas

Top episodios

Acerca de